DelveInsight: Market Research Reports

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Dopaminergic system Antagonist The report assesses ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “DP1 Receptor (Prostaglandin D2 receptor) Antagonist The ...

... encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Eg5 Inhibitor The report assesses the active Eg5 Inhibitor pipeline ...

... product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Elastase Inhibitor ...

... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Endothelin Receptor (ET) Antagonist The report ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Endothelin Receptor A (ETA) Antagonist The report ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Enhancer of zeste homolog 2 (EZH2) Inhibitor The report ...

... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Ephrin (EPH) Receptor Antagonist The report ...

... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Ephrin Type A Receptor 2 (EPH Receptor A2 or EPHA2) Antagonist ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Epithelial Sodium Channel (ENaC) Inhibitor The report ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Estrogen Receptor Beta Partial Agonist The report ...

... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor II (Prothrombin) Inhibitor The report ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor IIa (Thrombin) Inhibitor The report assesses ...

... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor IX The report assesses the active Factor IX pipeline ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor IX A Inhibitor The report assesses ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor VIIa Inhibitor The report assesses the active Factor VIIa ...

... of Ablynx and SHP655 of Shire. Products covered by Phase Filed & Phase III Inactive (Dormant and Discontinued) Overview of pipeline development activities for Factor VIII Inhibitor Pipeline analysis of therapeutic drugs include but are ...

... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Farnesoid X Receptor (FXR) Agonist The report ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fatty Acid Amide Hydrolase (FAAH) Inhibitor The report ...

... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fatty Acid Synthase (FAS) Inhibitor The report ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fc-Gamma Receptor Antagonist The report assesses ...

... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fibroblast Activation Protein (FAP or Seprase) Inhibitor The ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fibroblast Growth Factor (FGF) Inhibitor The report ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fibroblast Growth Factor 1 (FGF-1) Inhibitor The report ...

... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitor The ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Focal Adhesion Kinase (FAK) Inhibitor The report ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fusion Inhibitor The report assesses the active Fusion Inhibitor ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “G2 Checkpoint Inhibitor The report assesses ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “GABA Receptor Agonist The report assesses the active GABA Receptor ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “GABA Receptor Modulators The report assesses ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “GABA Transaminase Inhibitor The report assesses ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “GABAA Agonist The report assesses the active GABAA Agonist pipeline ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “GABAA Modulators The report assesses the active GABAA Modulators ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “GABAB Agonist The report assesses the active GABAB Agonist pipeline ...

... product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Galectin Inhibitor ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Gamma Secretase Inhibitor The report assesses ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Ghrelin Receptor Agonist The report assesses ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glucagon Receptor Antagonist The report assesses ...

... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glucagon-Like Peptide (GLP) Agonist The report ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glucocorticoid induced tumor necrosis factor The report ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glucocorticoid Receptor (GR) Antagonist The report ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glucokinase Activators The report assesses the active Glucokinase ...

... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glucosylceramide Synthase Inhibitor The report ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glutamate Receptor Antagonist The report assesses ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glycan Inhibitor The report assesses the active Glycan Inhibitor ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glycine Transporter Type-1 (Glyt-1) Inhibitor The ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glycogen Synthase Kinase 3 (GSK-3) Inhibitor The report ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “GM-CSF Inhibitor The report assesses the active GM-CSF Inhibitor ...

... , product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Gonadotropin-Releasing Hormone (GnRH) Receptor (LHRH Receptor) Antagonist The ...